|
Video: What is a Stock Split?
|
|
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. According to our TNXP split history records, Tonix Pharmaceuticals Holding has had 5 splits. | |
|
Tonix Pharmaceuticals Holding (TNXP) has 5 splits in our TNXP split history database. The first split for TNXP took place on March 17, 2017. This was a 1 for 10 reverse split, meaning for each 10 shares of TNXP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. TNXP's second split took place on November 28, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of TNXP owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 10 share position following the split. TNXP's third split took place on November 01, 2019. This was a 1 for 10 reverse split, meaning for each 10 shares of TNXP owned pre-split, the shareholder now owned 1 share. For example, a 10 share position pre-split, became a 1 share position following the split. TNXP's 4th split took place on May 17, 2022. This was a 1 for 32 reverse split, meaning for each 32 shares of TNXP owned pre-split, the shareholder now owned 1 share. For example, a 1 share position pre-split, became a 0.03125 share position following the split. TNXP's 5th split took place on June 10, 2024. This was a 1 for 32 reverse split, meaning for each 32 shares of TNXP owned pre-split, the shareholder now owned 1 share. For example, a 0.03125 share position pre-split, became a 0.0009765625 share position following the split.
When a company such as Tonix Pharmaceuticals Holding conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the TNXP split history from start to finish, an original position size of 1000 shares would have turned into 0.0009765625 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Tonix Pharmaceuticals Holding shares, starting with a $10,000 purchase of TNXP, presented on a split-history-adjusted basis factoring in the complete TNXP split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/11/2014 |
|
End date: |
12/09/2024 |
|
Start price/share: |
$6,819,840.00 |
|
End price/share: |
$0.19 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-100.00% |
|
Average Annual Total Return: |
-82.43% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$0.00 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
03/17/2017 | 1 for 10 | 11/28/2018 | 1 for 10 | 11/01/2019 | 1 for 10 | 05/17/2022 | 1 for 32 | 06/10/2024 | 1 for 32 |
|
|